Insider Trading › ATOS › Insiders

ATOSSA THERAPEUTICS, INC.

ATOS·Nasdaq·United States United States·Insider activity
$2.46
+0.01 (+0.41%)
Close · Oct 7, 2026 · Close Prices from Tiingo.com
ATOS
Insider purchases and sales on the price
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ATOSS&P 500 (rebased)
Insider BuyInsider SellForm 144 · planned sale
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

No open-market insider purchases or sales of ATOS were filed in the last 180 days. Newest filing May 22, 2025 (1 year ago).

Net Insider Buying by Quarter

Shares bought (+) or sold (−) on the open market by ATOS insiders · Form 4 · last two years
-20.0K-10.0K010.0K20.0K2025 Q1: 10.0K2025 Q12025 Q2: 11.2K2025 Q22025 Q3: 02025 Q32025 Q4: 02025 Q42026 Q1: 02026 Q12026 Q2: 02026 Q22026 Q3: 02026 Q32026 Q4: 02026 Q4

On Record

$0Purchases · 180 days
$0Sales · 180 days
24Open-market transactions on record
0Insiders filing · 180 days

Purchases (code P) and sales (code S) of ATOS common stock reported on Form 4, with Form 5 annual catch-ups. Grants, option exercises, gifts and tax withholding are not shown. Dollars are shares × the stated price; a price outside anything the stock traded at that day is withheld (n/c).

Insider Transactions

24 on record · newest trade first
AllPurchasesSalesOfficers & directors
InsiderTypeSharesPriceValueHeld afterTradedFiled
QUAY STEVEN CPresident & CEO · Director Purchase +11.2K $0.88 $10K13.9Kdirect May 21, 2025May 22, 2025 Form 4 ↗
Remmel H. LawrenceDirector Purchase +10.0K $0.70 $7K10.3Kdirect Mar 26, 2025Mar 28, 2025 Form 4 ↗
Finn JonathanDirector Purchase +25.0K $1.77 $44K25.0Kdirect Apr 10, 2024Apr 11, 2024 Form 4 ↗
WEAVER GREGORY LFormer EVP, CFO, & Director · Director Sale −50.0K $0.65 $33K55direct Nov 15, 2023Nov 17, 2023 Form 4 ↗
WEAVER GREGORY LEVP & CFO · Director Purchase +50.0K $0.97 $49K50.1Kdirect Jun 20, 2023Jun 20, 2023 Form 4 ↗
WEAVER GREGORY LDirector Sale −107.5K $5.58 $600K0direct Jul 2, 2021Jul 7, 2021 Form 4 ↗
Guse KyleCFO, Gen Counsel and Secretary Purchase +1,400 $0.34 $47610.0Kdirect Nov 15, 2017Nov 16, 2017 Form 4 ↗
Guse KyleCFO, Gen Counsel and Secretary Purchase +8,600 $0.34 $3K8,600direct Nov 15, 2017Nov 16, 2017 Form 4 ↗
Remmel H. LawrenceDirector Purchase +2,500 $0.63 $2K3,126direct Apr 17, 2017Apr 18, 2017 Form 4 ↗
Remmel H. LawrenceDirector Purchase +1,500 $0.33 $49510.9Kdirect Apr 1, 2016Apr 4, 2016 Form 4 ↗
Chen Shu-ChihDirector · 10% owner Purchase +15.0K $0.37 $6K4.3Mindirect Mar 9, 2016Mar 10, 2016 Form 4 ↗
QUAY STEVEN CPresident & CEO · Director · 10% owner Purchase +15.0K $0.37 $6K4.8Mindirect Mar 9, 2016Mar 10, 2016 Form 4 ↗
QUAY STEVEN CPresident & CEO · Director · 10% owner Purchase +15.0K $0.53 $8K4.8Mindirect Feb 16, 2016Feb 17, 2016 Form 4 ↗
Chen Shu-ChihDirector · 10% owner Purchase +15.0K $0.53 $8K4.3Mindirect Feb 16, 2016Feb 17, 2016 Form 4 ↗
Chen Shu-ChihDirector · 10% owner Purchase +50.0K $0.20 $10K4.3Mindirect Jan 19, 2016Jan 21, 2016 Form 4 ↗
QUAY STEVEN CPresident & CEO · Director · 10% owner Purchase +50.0K $0.20 $10K4.8Mindirect Jan 19, 2016Jan 21, 2016 Form 4 ↗
Remmel H. LawrenceDirector Purchase +5,400 $1.30 $7K9,400direct Jun 12, 2015Jun 15, 2015 Form 4 ↗
WEAVER GREGORY LDirector Purchase +10.0K $2.58 $26K34.5Kdirect Nov 21, 2013Nov 22, 2013 Form 4 ↗
QUAY STEVEN CCEO · Director · 10% owner Sale −7,265 $5.66 $41K4.3Mindirect Oct 1, 2013Oct 3, 2013 Form 4 ↗
Chen Shu-ChihChief Scientific Officer · Director · 10% owner Sale −7,265 $5.66 $41K4.3Mindirect Oct 1, 2013Oct 3, 2013 Form 4 ↗
CROSS ALEXANDER DDirector Purchase +500 $5.49 $3K88.9Kindirect May 15, 2013Jun 27, 2013 Form 4 ↗
Remmel H. LawrenceDirector Purchase +2,000 $4.05 $8K2,000indirect Jan 8, 2013Jan 9, 2013 Form 4 ↗
Remmel H. LawrenceDirector Purchase +1,600 $4.20 $7K2,000direct Jan 8, 2013Jan 9, 2013 Form 4 ↗
Remmel H. LawrenceDirector Purchase +400 $4.10 $2K400direct Jan 8, 2013Jan 9, 2013 Form 4 ↗

Source: SEC EDGAR Form 4 and Form 5 filings, SEC's quarterly bulk dataset through Jun 30, 2026, and KeyVex's half-hourly read of new filings since. Every row links its filing. Amendments are marked. Nothing here is a recommendation. All insider activity, market-wide →